Boston Scientific Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boston Scientific Corporation
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.
- Implantable Devices
- Monitoring Equipment & Devices
- Radiofrequency Devices
- Rehabilitation Equipment and Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
- Apama Medical
- Atritech, Inc.
- Augmenix, Inc.
- Biocompatibles International plc
- BridgePoint Medical, Inc.
- BTG plc
- BTG Specialty Pharmaceuticals
- Cameron Health, Inc.
- Cardiovascular Imaging Systems, Inc.
- Cosman Medical Inc.
- Cryterion Medical, Inc.
- Devoro Medical, Inc.
- Ekos Corporation
- EMcision, Ltd.
- EndoTex Interventional Systems, Inc.
- EndoChoice Holdings, Inc.
- Enteric Medical Technologies, Inc.
- Galil Medical, Inc.
- Guidant Corporation
- Intelect Medical, Inc.
- IoGyn, Inc.
- Labcoat Limited
- Meadox Medicals, Inc.
- Novate Medical Ltd.
- nVision Medical Corporation
- NxThera, Inc.
- Pathworks Anatomic Pathology Laboratory
- PneumRx Inc.
- Precision Vascular Systems, Inc.
- Protherics PLC
- RadioTherapeutics Corporation
- Revascular Therapeutics, Inc.
- Roxwood Medical
- Rubicon Medical Corporation
- SCIMED, Inc.
- Securus Medical Group, Inc.
- Symetis SA
- Vessix Vascular, Inc.
- Xlumena Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.